Hormone replacement therapy (HRT) with conjugated equinestrogens (CEE) plus medroxyprogeserone acetate (MPA) or CEE alone does not increase the risk of cardiovascular (CV) mortality among postmenopausal women, according to an expert who reviewed 18-year follow-up data of the Women’s Health Initiative (WHI) randomized trials at the Endocrinology, Diabetes Metabolism Hong Kong (EDMHK) 2nd Annual Meeting.
Denosumab is superior to risedronate in increasing spine and hip bone mineral density (BMD) through month 24 and may be a new treatment option for patients with glucocorticoid-induced osteoporosis (GIOP), according to results of a multicentre, randomized, phase III trial.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.